TSX open
Loading markets…

Advertisement

Stocks

Why Amgen stock is rising today

By Wealth Awesome -

Follow live quotes and coverage.

Stocks & ETFs:AMGN.US

Follow AMGN

Photos provided by Pexels

Amgen Inc. is experiencing a notable rise in its stock price, reflecting positive investor sentiment.

Amgen Inc. (NASDAQ:AMGN) is rising today, gaining 2.28% to close at CA$416.72. This uptick comes amid a favorable earnings outlook and positive revisions in analyst expectations.

Advertisement

Amgen Inc

AMGN.US

Full stock page →

AMGN.US

Amgen Inc

Source:WealthAwesomeWealthAwesome
↑ $61.92 (17.92%)
120 day period
$319.56$381.84$444.12Apr 20Jul 16Oct 8

Market cap

$223.32B

P/E

25.0x

Div. yield

2.43%

Div. / share

$9.80

52W high

$447.03

52W low

$280.23

1W change

+0.04%

Beta

0.41

Analyst Price Targets

Based on 34 analysts covering AMGN · as of Oct 9, 2026

📉

Wall Street analysts forecast AMGN stock price to fall 3.9% over the next 12 months.

Consensus

Hold

3.35 / 5.00

Avg. Target

C$391.46

-3.9% Upside

Previously C$390.94 on Oct 5, 2026

Current Price

C$407.44

Last close

Analyst Breakdown (34 analysts)

Strong Buy 8
Buy 4
Hold 17
Sell 2
Strong Sell 3
Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on AMGN's historical volatility

HistoricalForecast68%95%
C$292.43C$396.07C$499.71C$603.35C$706.99C$810.63TodayJun 2Aug 6Oct 8Nov 20Jan 3Feb 15

30-Day Vol

40.1%

Annualized

90-Day Vol

32.5%

Annualized

Trend (90d)

+50.0%

Annualized drift

90d Mean

C$487.10

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$432.43C$376.50 – C$496.67
60 trading daysC$458.95C$377.31 – C$558.25
90 trading daysC$487.10C$383.21 – C$619.16

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Advertisement

Investor takeaway: Investors may find Amgen's current performance encouraging, particularly with its strong revenue growth and positive analyst sentiment ahead of the upcoming earnings season.

Amgen's Stock Gains 2.28%

The stock's rise today reflects growing investor confidence, supported by favorable earnings revisions and positive market sentiment.

Bull case

Amgen's recent earnings report showed a 9.5% year-over-year revenue increase, surpassing analysts' expectations. The company also received an A+ EPS revision grade, indicating strong analyst confidence in its future performance.

Bear case

While the stock is performing well, investors should remain cautious about potential market volatility and external pressures, such as competition in the biotech sector and regulatory challenges.

Strong Earnings Performance

Advertisement

Amgen's recent earnings report highlighted a 9.5% increase in revenue year-over-year, reaching $10.05 billion. This performance not only exceeded analysts' expectations but also set a positive tone for the upcoming earnings season, as the company continues to show resilience in a competitive market.

Analyst Upgrades Boost Confidence

Analysts have shown increased confidence in Amgen's future performance, awarding the company an A+ EPS revision grade. This rating reflects a favorable shift in earnings expectations, contributing to the stock's rise as investors anticipate continued growth.

Market Sentiment and Future Outlook

The overall market sentiment towards biotechnology stocks remains cautiously optimistic, with Amgen positioned well to capitalize on upcoming trends in the healthcare sector. However, investors should stay alert to potential risks, including regulatory challenges and market fluctuations that could impact performance.


Advertisement

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: October 9, 2026
Last Updated: October 9, 2026

Core portfolio

Awesome Portfolio™

14.8% a year since 2017, against 9.7% for the S&P/TSX Composite. Ten stocks, easy to manage. We update it once a month.

Annualized

+14.8%

Awesome Portfolio™

+9.7%

S&P/TSX

+5.0 pp better a year

Total return

+254%

Awesome Portfolio™

+134%

S&P/TSX

+119 pp better than the TSX

2017-07-31 to 2026-09-29, dividends reinvested, before fees and tax.

Awesome Portfolio™S&P/TSX CompositeCumulative return · 2017-07-31–2026-09-29
-11.7%42.5%96.7%150.9%205.1%259.3%Jul 17Oct 19Feb 22Jun 24Sep 26

Sponsored links

Advertisement